February 5, 2024

West Chester PA – Papyrus Therapeutics Inc., a biotechnology platform company for the development of potent, multi-cancer, tumor suppressor precision therapies for solid cancers, is pleased to announce the upcoming poster presentation entitled “Oncolytic Vaccinia Virus Carrying OPCML Tumor Suppressor is active in Epithelial Ovarian Cancer” has been accepted for presentation at the forthcoming AACR meeting in San Diego in the Immunology category from 9.00am – 12.30pm PT on April 10th (https://www.aacr.org/meeting/aacr-annual-meeting-2024/).

The data demonstrate that vaccinia virus directed OPCML protein expression enhances OVV selectivity against ovarian cancer cells through direct oncolysis, inhibition of specific RTKs, suppression of angiogenesis, and activation of antitumor immune responses synergistically when combined with an anti-PD-1 inhibitor.

According to Papyrus’ co-founder / chief scientific officer, and renowned translational medical oncologist Hani Gabra, PhD FRCP, “A short treatment with novel OVV-OPCML / anti-PD-1 inhibitor combination showed a 50% increase in median survival in the mice studied, an encouraging outcome demonstrating promise as a targeted strategy for ovarian cancer treatment. This is important given the relatively poor treatment results with check-point inhibitors to date in ovarian cancer.”

About Papyrus Therapeutics Inc.:

Papyrus Therapeutics, Inc. (https://papyrustherapeutics.com/) is a biotherapeutics platform company developing novel tumor suppressor-based therapies. Papyrus ́ lead therapeutic is a modified, recombinant analogue of Opioid Binding Protein/Cell Adhesion Molecule-like (r-OPCML-Fc), PYTX-004. PYTX-004 is a native engineered OPCML protein replacement therapy designed to suppress tumor growth. OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Delivery of OPCML, which works at the cell surface, can overcome the challenge of RTK inhibitor resistance by reconstituting normal RTK signaling in the tumor.

Forward looking statements:

This press release contains “forward-looking statements” concerning the development of Papyrus Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Papyrus Therapeutics undertakes no obligation to update any forward-looking statements for any reason.


Dr. Paul Blake